glp-1 and diverticulitis Effect of Weight Loss on Clinical Outcomes in Patients With Chronic Gastrointestinal and Liver Diseases Semaglutide and Diverticulitis: Safety Guide

PetitJMCercueilJPLoffroyRDenimalDBouilletBFourmontCet al

When we eat, GLP-1 is released in our intestines, signaling the pancreas to produce insulin and helping us feel full

For some patients, weight regain despite intensive lifestyle efforts may warrant consideration of resuming tirzepatide or transitioning to alternative anti-obesity medications, provided they meet FDA-indicated criteria (BMI 30 kg/m or 27 kg/m with weight-related comorbidity)

Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population

Ozempic, which has a lower dose of 0.5-2 semaglutide, is FDA-approved for diabetes control, while higher-dose semaglutide, Wegovy, is approved for weight loss